Updated Jul 16, 2026
Stapley Marc has filed 3 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $10.95M.
Marc Stapley is the Chief Executive Officer and a Director at Veracyte, Inc., a genomic diagnostics company focused on cancer diagnostics. He has held leadership roles in the healthcare sector, contributing to advancements in genomic testing.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | VCYT | VERACYTE, INC. | S — Open-market sale | 138.1K | $50.12 | $6.92M |
| 2026-06-05 | VCYT | VERACYTE, INC. | M — Option exercise | 138.1K | $36.60 | $5.05M |
| 2026-06-05 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 9.0K | $47.80 | $431K |
| 2026-06-01 | GKOS | GLAUKOS Corp | A — Grant or award | 1.9K | $0.00 | |
| 2026-03-10 | VCYT | VERACYTE, INC. | A — Grant or award | 92.1K | $0.00 | |
| 2026-03-06 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 26.3K | $36.28 | $953K |
| 2026-03-06 | VCYT | VERACYTE, INC. | S — Open-market sale [10b5-1] | 19.2K | $35.56 | $684K |
| 2026-03-04 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 19.5K | $36.01 | $701K |
| 2026-03-02 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 35.8K | $38.75 | $1.39M |
| 2026-03-02 | VCYT | VERACYTE, INC. | A — Grant or award | 139.1K | $0.00 | |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 1.3K | $129.78 | $169K |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 4.3K | $129.11 | $558K |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 1.7K | $127.92 | $214K |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 3.9K | $126.96 | $494K |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 3.8K | $126.07 | $481K |
| 2026-01-27 | GKOS | GLAUKOS Corp | M — Option exercise [10b5-1] | 15.0K | $24.69 | $370K |
| 2026-01-08 | GKOS | GLAUKOS Corp | A — Grant or award | 727 | $0.00 | |
| 2025-09-04 | VCYT | VERACYTE, INC. | S — Open-market sale | 7.7K | $30.41 | $233K |
| 2025-09-02 | VCYT | VERACYTE, INC. | F — Tax withholding / forfeiture | 7.9K | $30.11 | $238K |
| 2025-01-02 | GKOS | GLAUKOS Corp | A — Grant or award | 2.1K | $0.00 |
Marc Stapley is the Chief Executive Officer and a Director at Veracyte, Inc., a genomic diagnostics company focused on cancer diagnostics. He has held leadership roles in the healthcare sector, contributing to advancements in genomic testing.…
3 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 11 open-market sales ($10.95M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Stapley Marc profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.